The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Fedoseeva I.F.

Kemerovo State Medical University

Goncharenko A.V.

Kemerovo State Medical University

Goncharenko V.A.

Kemerovo State Medical University

Poponnikova T.V.

Kemerovo State Medical University

Pinevich O.S.

Kuzbass Regional Clinical Hospital named after S.V. Belyaev

Bedareva T.Yu.

Kuzbass Regional Clinical Hospital named after S.V. Belyaev

A clinical case of type 1 neurofibromatosis associated with a rare genotype

Authors:

Fedoseeva I.F., Goncharenko A.V., Goncharenko V.A., Poponnikova T.V., Pinevich O.S., Bedareva T.Yu.

More about the authors

Read: 752 times


To cite this article:

Fedoseeva IF, Goncharenko AV, Goncharenko VA, Poponnikova TV, Pinevich OS, Bedareva TYu. A clinical case of type 1 neurofibromatosis associated with a rare genotype. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(6):128‑132. (In Russ.)
https://doi.org/10.17116/jnevro2025125061128

Recommended articles:

References:

  1. Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet. 2001;68(5):1110-1118. https://doi.org/10.1086/320121
  2. Landry JP, Schertz KL, Chiang YJ, et al. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open. 2021;4(3):e210945. https://doi.org/10.1001/jamanetworkopen.2021.0945
  3. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A(2):327-332.  https://doi.org/10.1002/ajmg.a.33139
  4. Farschtschi S, Mautner VF, McLean ACL, et al. The Neurofibromatoses. Dtsch Arztebl Int. 2020;117(20):354-360.  https://doi.org/10.3238/arztebl.2020.0354
  5. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834-843.  https://doi.org/10.1016/S1474-4422(14)70063-8
  6. Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23(8):1506-1513. https://doi.org/10.1038/s41436-021-01170-5
  7. Peduto C, Zanobio M, Nigro V, et al. Neurofibromatosis Type 1: Pediatric Aspects and Review of Genotype-Phenotype Correlations. Cancers (Basel). 2023;15(4):1217. https://doi.org/10.3390/cancers15041217
  8. Koczkowska M, Chen Y, Callens T, et al. Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. Am J Hum Genet. 2018;102(1):69-87.  https://doi.org/10.1016/j.ajhg.2017.12.001
  9. Lugovskaya AY, Britvin TA, Gurevich LE, et al. Neurofibromatosis type 1 associated with pheochromocytoma: a case report with a brief review of the literature. Problems of Endocrinology. 2024;70(2):53-64. (In Russ.) https://doi.org/10.14341/probl13345
  10. Kehrer-Sawatzki H, Wahlländer U, Cooper DN, Mautner VF. Atypical NF1 Microdeletions: Challenges and Opportunities for Genotype/Phenotype Correlations in Patients with Large NF1 Deletions. Genes (Basel). 2021;12(10):1639. https://doi.org/10.3390/genes12101639
  11. Pacot L, Girish M, Knight S, et al. Correlation between large rearrangements and patient phenotypes in NF1 deletion syndrome: an update and review. BMC Med Genomics. 2024;17(1):73.  https://doi.org/10.1186/s12920-024-01843-5
  12. Savad S, Modarressi MH, Younesi S, et al. A Comprehensive Overview of NF1 Mutations in Iranian Patients. Neuromolecular Med. 2024;26(1):28.  https://doi.org/10.1007/s12017-024-08790-5
  13. Du Q, Chen H, Zhou H. Deletion of the whole NF1 gene in a three-generation family with neurofibromatosis type 1. Neurol Sci. 2022;43(2):1295-1301. https://doi.org/10.1007/s10072-021-05353-5
  14. Sánchez Marco SB, López Pisón J, Calvo Escribano C, et al. Neurological manifestations of neurofibromatosis type 1: our experience. Manifestaciones neurológicas en neurofibromatosis tipo 1. Nuestra experiencia. Neurologia (Engl Ed). 2022;37(5):325-333.  https://doi.org/10.1016/j.nrl.2019.05.003
  15. Mallone F, Lucchino L, Giustini S, et al. An update on choroidal abnormalities and retinal microvascular changes in neurofibromatosis type 1. Orphanet J Rare Dis. 2022;17(1):223.  https://doi.org/10.1186/s13023-022-02369-8
  16. Moramarco A, Mallone F, Sacchetti M, et al. Hyperpigmented spots at fundus examination: a new ocular sign in Neurofibromatosis Type I. Orphanet J Rare Dis. 2021;16(1):147.  https://doi.org/10.1186/s13023-021-01773-w
  17. Mezad-Koursh D, Bachar Zipori A, Zur D, et al. Visual function tests including the role of optical coherence tomography in neurofibromatosis 1. Childs Nerv Syst. 2020;36(10):2363-2375. https://doi.org/10.1007/s00381-020-04706-3
  18. Miyagishima KJ, Qiao F, Stasheff SF, Nadal-Nicolás FM. Visual Deficits and Diagnostic and Therapeutic Strategies for Neurofibromatosis Type 1: Bridging Science and Patient-Centered Care. Vision (Basel). 2024;8(2):31.  https://doi.org/10.3390/vision8020031
  19. Chen Y, Yu J, Ge S, et al. An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic Strategies. Invest Ophthalmol Vis Sci. 2024;65(6):8.  https://doi.org/10.1167/iovs.65.6.8
  20. Pan Y, Hysinger JD, Barron T, et al. NF1 mutation drives neuronal activity-dependent initiation of optic glioma. Nature. 2021;594(7862):277-282.  https://doi.org/10.1038/s41586-021-03580-6
  21. Zhou WT, Niu JH, Liao C, et al. Visual deterioration outcomes following optic pathway glioma treatment: a 12-year single institution retrospective study. J Neurooncol. 2024;170(2):363-375.  https://doi.org/10.1007/s11060-024-04802-3
  22. Azizi AA, Walker DA, Liu JF, et al. NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. Neuro Oncol. 2021;23(1):100-111.  https://doi.org/10.1093/neuonc/noaa153
  23. Kotch C, Avery R, Getz KD, et al. Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1. Neuro Oncol. 2022;24(8):1377-1386. https://doi.org/10.1093/neuonc/noac013
  24. Thomas S, Bikeyeva V, Abdullah A, et al. Systematic Review of Pediatric Brain Tumors in Neurofibromatosis Type 1: Status of Gene Therapy. Cureus. 2022;14(8):e27963. https://doi.org/10.7759/cureus.27963
  25. Amato A, Imbimbo BP, Falsini B. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments. Eur Rev Med Pharmacol Sci. 2023;27(12):5636-5653. https://doi.org/10.26355/eurrev_202306_32804
  26. Rebelo M, Francisco T, Perry da Câmara R, et al. Multidisciplinary Outpatient Clinic of Neurocutaneous Diseases: Five-year Experience of a Pediatric Tertiary Hospital in Portugal. Acta Med Port. 2024;37(3):187-197.  https://doi.org/10.20344/amp.19063

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.